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1. Introduction  
“Tobacco is the single most preventable cause of death in the world today. This year, tobacco will kill 
more than five million people – more than tuberculosis, HIV/AIDS and malaria combined. By 2030, 
the death toll will exceed eight million a year. Unless urgent action is taken tobacco could kill one 
billion people during this century. Tobacco is the only legal consumer product that can harm 
everyone exposed to it – and it kills up to half of those who use it as intended.” (WHO Report on the 
global tobacco epidemic, 2008, p. 8) 
Although nearly all smokers are aware of the outstanding healthy risks of cigarette smoking 
and the majority of them is willing to quit, only a small proportion of regular smokers is 
able to stop smoking successfully. Within 12 months after a stop smoking trial, only 2-6% of 
quitters remain abstinent. This high relapse rate can only be explained by mechanisms of 
addiction. The term “tobabacco addiction” refers to the definition of substance use disorders, 
which includes harmful substance use as well as physiological and psychological 
dependence. This chapter aims to summarize the current state of knowledge regarding to 
the phenomenon of tobacco addiction and tobacco use related disorder. 
2. Classification, epidemiology, etiology, and treatment of tobacco addiction 
2.1 Diagnostic classification 
Tobacco addiction states a mental disorder with severe somatic and mental symptoms and 
consequences. The term 'addiction' was, due to its terminological vagueness, discarded as an 
official name for a diagnostic category by the WHO in 1964, however it is still used today in 
everyday speech and as part of the technical language. Within the current clinical classification 
systems DSM-IV and ICD-10 the phenomene of addiction caused by psychotropic substances 
is classified in two different diagnostic categories: DSM-IV differenciates ‘substance dependence’ 
(303.xx) and ‘substance abuse’ (305.xx) whereas ICD-10 refers to ‘dependence’ and ‘harmful use’ 
(F1x.1).  According to DSM, drug dependence is defined by seven diagnostic core criteria of 
which three must be met along with clinically important suffering in order to confirm the 
diagnosis. In contrast, abuse is determined by repeated, maladjusted substance use and 
psychosocial impairments (e.g., interpersonal problems, legal problems, high risk behaviour) 
over a period of at least 12 months (cf. Tab. 1). 
There is a clinical and neurobiological distinction between somatic and mental addiction. 
Somatic addiction is primarily defined by development of tolerance and physiological 
withdrawal symptoms. That means, the organism "gets used" to the regular dose of the 
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DSM-IV-TR DSM-V 
Nicotine Abuse Nicotine 
Dependence
Tobacco Use Disorder
at least one of the 
following criteria 
within the same 
12 months 
period: 
(1) Severe 
problems 
regarding family, 
home, profession 
or school due to 
substance use 
(2) Substance use 
in dangerous 
situations 
(3)Legal 
problems due to 
substance use 
(4) Social and/or 
interpersonal 
problems due to 
substance use 
 
The symptoms 
have never 
fulfilled the 
criteria for 
substance 
addiction of the 
respective 
substance class. 
 
at least three of the 
following criteria 
within the same 
12 months period: 
(1) Development 
of tolerance 
(2) Withdrawal 
symptoms 
(3) Substance use 
longer or in larger 
quantities than 
intended 
(4) Permanent 
wish or failure to 
control substance 
use 
(5) Time-
consuming 
procurement, use 
and recovery 
from substance 
(6) Important 
social, 
professional or 
recreational 
activities are 
given up or 
limited due to 
substance use 
(7) Continued 
substance use 
despite physical 
or psychic 
problems 
maladaptive pattern of substance use leading to 
clinically significant impairment or distress, as 
manifested by 2 (or more) of the following, occurring 
within a 12-month period: 
1. recurrent substance use resulting in a 
failure to fulfill major role obligations at 
work, school, or home  
2. recurrent substance use in situations in 
which it is physically hazardous  
3. continued substance use despite having 
persistent or recurrent social or 
interpersonal problems caused or 
exacerbated by the effects of the substance  
4. tolerance, as defined by either of the 
following: a need for markedly increased 
amounts of the substance to achieve 
intoxication or desired effect b) markedly 
diminished effect with continued use of the 
same amount of the substance 
5. withdrawal, as manifested by either of the 
following: a) the characteristic withdrawal 
syndrome for the substance; b) the same (or 
a closely related) substance is taken to 
relieve or avoid withdrawal symptoms 
6. the substance is often taken in larger 
amounts or over a longer period than was 
intended  
7. there is a persistent desire or unsuccessful 
efforts to cut down or control substance use  
8. a great deal of time is spent in activities 
necessary to obtain the substance, use the 
substance, or recover from its effects  
9. important social, occupational, or 
recreational activities are given up or 
reduced because of substance use  
10. the substance use is continued despite 
knowledge of having a persistent or 
recurrent physical or psychological 
problem that is likely to have been caused 
or exacerbated by the substance  
11. Craving or a strong desire or urge to use a 
specific substance. 
Table 1. Tobacco-related Disorders according to DSM-IV-TR vs. DSM-V. 
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substance and thus needs ever increasing amounts to reach the desired state of intoxication 
(dose increase), however, also can tolerate higher doses than at the beginning of drug use 
(tolerance).  In contrast, the mental addiction is characterized by behavioral patterns such as 
compulsive use, loss of control, addiction memory, craving and coping deficits. The term 
"addiction" refers more to the mental aspect of the dependency, i.e. to the continuing 
compulsive consumption of the drug despite negative effects and/or despite the wish to 
stop drug use. Whereas the somatic dependency syndrome is generally gone some weeks 
after the withdrawal, the addiction memory may remain active for years and decades and 
continue to trigger periodical craving or even relapses from time to time. Thus, a dependent 
smoker may have stopped to be dependent on tobacco after successful withdrawal therapy 
but he/she may remain addicted, possibly for his/her whole life.  
Within the process for revising the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-V) the work group which is responsible for addressing substance use disorders 
currently developed new recommendations to redefine these diagnostic categories. Among 
the work group’s proposals are the following recommendations: 
i. To move the categories of ‘abuse’ and ‘dependence’ in one common diagnosis category 
named ‘Substance-Related Disorders’; 
ii. To include both substance use disorders and non-substance addictions (Gambling 
disorder, Internet addiction) in this new diagnostic category  
iii. To tentatively re-title the category into the term ‘Addiction and Related Disorders’. 
In consequence, the diagnosis ‘Nicotine Dependence’ (305.1) should be replaced by ‘Tobacco 
Use Disorder’ which includes 11 diagnostic criteria (s. table 1). 
2.2 Epidemiology 
2.2.1 Prevalence of cigarette smoking and nicotine dependence 
The epidemiology of addictive smoking can be demonstrated by international point 
prevalence as well as life-time prevalence data of representative population-based health 
surveys. The rates of current smokers in adult population (> 14 years) are extremely varying 
by country and gender (figure 2).  
Approximately one half of the smoking men and one-third of the women are classified as 
heavy smokers (>20 cig./day). However, not every chronic cigarette smoker will necessarily 
become addicted to nicotine or tobacco. A number of international epidemiological studies 
found that only a minority of persistent smokers become dependent according the 
diagnostic criteria for substance use disorders described above. In a currently conducted, 
well controlled population survey on nearly 8,000 representative participants in Germany, 
6.3% participants among the total sample and 29.9% of all current smokers (smoking rate: 
29,6%) met the DSM-IV criteria for a nicotine dependence disorder (Papst et al., 2010). 
Nevertheless, nicotine dependence has an outstanding significance from an epidemiological 
perspective since, with a lifetime prevalence of 17% and 21% (cf. Tab. 2), it is one of the most 
common mental disorders, compared to affective disorders (lifetime prevalence: 12-19%) or 
anxiety disorders (LT prevalence:  15%). By trend, nicotine dependence occurred more often 
in female smokers and in younger age groups compared with older cohorts. In Lifetime, 
50% of all smokers succeed to quit, mostly after 5-10 ineffective attempts. 
Approximately every second smoker who has tried to quit smoking reports somatic 
withdrawal symptoms that manifest themselves in psycho-vegetative conditions or 
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cognitive-emotional adverse effects (cf. table 3). The nicotine withdrawal syndrome starts 2-4 
hours after the last cigarette, reaches its intensity peak after 24-48 hours and gradually 
passes after 1-4 weeks. However, the primarily mental symptoms (craving, feeling of 
hunger, dysphoria) may persist for months. 
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Fig. 1. WHO Report on the Global Tabacco Epidemic (2008) 
 
 
 Total Gender 
   Men Women 
Consumption prevalence (30 d)1 7,983  3,542 4,441 
Non-Smokers 44.8% (3,858) 38.8% 51.0% 
Ex-smokers 26.0% (1,771) 28.5% 23.6% 
Smokers 29.2% (2,354) 32.8% 25.5% 
Consumption frequency (30 d)2 2,238  1,096 1,142 
Not daily 29.6% (714) 28.4% 31.0% 
Daily up to 10 21.7% (530) 17.4% 27.1% 
Daily 11-19 23.5% (517) 25.7% 20.9% 
Daily more than 20 25.2% (477) 28.5% 21.1% 
DSM-IV (12M)3 7,984  3,521 4,427 
Total sample 6.3% (531) 6.8% 5.8% 
Consumers4 19.9% (531) 19.2% 20.9% 
1 Non-Smokers: have smoked a total of maximum 100 cigarettes; ex-smoker: have smoked more than 
100 cigarettes, but not in the previous 30 days; smokers: smoked cigarettes in the previous 30 days. 
2 Referring to cigarette smokers during the previous 30 days. 
3 Nicotine dependence according to DSM-IV: unweighted number of cases regarding to total sample 
4 Referring to 12 months prevalence of smoking. 
Table 2. Prevalence of smoking, of smoke frequency and nicotine dependence according to 
DSM-IV (Papst e al., 2010, p. 332) 
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 craving 
 increased appetite, sensation of hunger, weight gain 
 concentration problems 
 nervousness, irritability, restlessness, insomnia 
 feeling of frustration, unhappiness, depressive moods, depression, states of anxiety, 
anxieties 
 circulation problems, sweating, digestive disorders 
Table 3. Withdrawal symptoms during the smoke stop 
The strength of the nicotine dependency can best be measured through specific withdrawal 
symptoms. The Fagerstrom Test for Nicotine Dependence (FTND; Heatherton et al., 1991; cf. 
table 4), which consists of six items, is recommended worldwide as a dimensional research 
tool for the measurement of nicotine dependency. This test has been validated in 
international studies and represents one of the best predictors for abstinence success. 
 
 
Table 4. Fagerstrom Test for Nicotine Dependence (FTND; Heatherton et al., 1991) 
2.2.2 Addiction and risk potential of the drug tobacco 
The ‘addiction potential’ of a drug describes the risk for developing a mental or physical 
dependence when using a drug and the subsequent failure to quit the use and to master a 
withdrawal. This addiction risk results from a) the pharmacological effects of the substance 
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on the organism, b) the quality and intensity of the evoked subjective states of intoxication 
or well-being and c) the learned stimulus-response association between the drug use on the 
one hand and the ‘kick’ or flush response (positive reinforcement) and/or the avoidance of 
withdrawal symptoms on the other (negative reinforcement). The addiction potential of a 
psychotropic substance is not exclusively determined by its pharmacological characteristics 
and its potency for physical dependence but essentially, among other things, by the type of 
the substance intake (addiction potential decreasing with types of applications: injecting, 
sniffing, smoking and swallowing). This explains that smoked nicotine has a high addiction 
potential compared to nicotine patches at the same dose.  
Alongside heroin, nicotine is seen as the substance with the highest ’pure addiction 
potential’. This finding has been determined in animal studies wherein different 
substances are applied in standardised form (e.g. as an oral application). The measure for 
the addiction potential is typical addiction behaviour shown by the laboratory animals 
after a number of applications (e.g. number of lever actions or toleration of pain stimuli in 
order to get to the drug). However, the approaches for the determination of the addiction 
potential that are based on complex expert judgements on the addiction risk of persons 
under real using conditions seem to be more adequate. In a study conducted by the Swiss 
Institute for the Prevention of Alcohol and Drug Problems (SIPA), renowned addiction 
experts evaluated the addiction potential of seven different substances in direct 
comparison according to five evaluation criteria (cf., tab. 5). In the resulting ranking list 
heroin reached the highest addiction potential, followed by cocaine, alcohol and nicotine, 
whereby for nicotine especially a very high value for (mental) ‘addiction’ was declared 
(Fahrenkrug & Gmel, 1996). 
 
Substance 
Overall 
Evaluation
With-
drawal 
Symptoms
Reinforce-
ment 
Increase of 
Tolerance 
Addiction Intoxication 
Heroin 1 1 1 1 1 2 
Cocaine 2 3 2 3 3 1 
Alcohol 3 2 4 2 4 3 
Nicotine 4 4 3 4 2 6 
Caffeine 7 7 7 6 7 7 
Ecstasy 5 5 5 5 5 4 
Marihuana 6 6 6 7 6 5 
1= highest addiction potential; 7= lowest addiction potential 
Table 5. Addiction Potential of Different Psychotropic Substances (quoted in Fahrenkrug & 
Gmel, 1996). 
The ‘addiction potential’ relates to the addiction risk, but does not state anything about 
the overall biopsychosocial risk potential of a drug. Nutt et al. (2007) determined three main 
factors of potential damage by a psychotropic substance: 1) physical damage, 2) addiction 
potential and 3) social effects. A three-dimensional risk categories matrix was derived 
from this, by means of which the different substances were evaluated by two independent 
expert groups regarding their overall risk potential. In this multi-dimensional evaluation 
of the biopsychosocial overall risks, tobacco smoking is positioned in the upper middle 
field (place 9).  
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2.2.3 Comorbidity: Tobacco smoking and mental disorders 
Tobacco addiction is closely associated with the occurrence of mental disorders and their 
course of disease. Cigarette smoking is disproportionately prevalent amongst persons with 
mental disorders (population) and/or psychiatric patients (clinical populations; Breslau, 
1995; Degenhardt & Hall, 2001; John et al., 2004; Meyer et al, 2004; Haug et al., Heinberg & 
Guarda, 2001; Kordon & Kahl, 2004). On the whole, prevalence of smoking in mentally 
comorbid persons is approximately twice as high (50%) when compared to the general 
population (25-30%) (Grant et al., 2004; Lasser et al., 2000). It even amounts to 71-90% in 
patients with addictions to other substances (Ker et al., 1996; Patten et al., 1996; Martin et al., 
1997; Williams & Ziedonis, 2004); for other severe types of disorders such as schizophrenia and 
bipolar disorders prevalence is on average 80% (Hughes, 1993; Leon & Diaz, 2005). In the 
US, the market share of the overall cigarette consumption by persons with psychiatric 
diagnoses is currently between 44 and 46% (Lasser et al., 2000; Grant et al., 2004). 
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Fig. 2. Co-Morbidity of Smoking in Patients with Psychiatric and Substance Use Disorders 
(Kalman et al., 2005, p. 107) 
Smokers with mental comorbidity mostly are heavy smokers, that means they are prone to 
smoke more cigarettes per day (days pack) and to smoke each cigagette more intensively 
(e.g. draws per cigarette, draw frequency, inhalation depth) (Lasser et al., 2000; Tidey et al., 
2005). As a result, they do not only show increased physic long-term morbidity and 
mortality rates due to organic diseases associated with tobacco (Williams & Ziedonis, 2004), 
but they also have, amongst other things, a worse prognosis in relation to their mental 
disorder, a higher psychiatric lifetime-co-/multimorbidity, a more unfavourable course of 
disease (e.g. episodes in MDE that are more often, longer and more intensive), less 
successful therapy outcomes, a higher burden of disease, severe impairment of psychosocial 
functioning (Brown et al. 2000) as well as a lower quality of life (Schmitz et al., 2003). Smokers 
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suffering from a mental disorder also show a lower self-efficacy and more negative attitudes 
towards a smoke stop (Carossella et al., 1999; Esterberg & Compton, 2005) as well as below 
average success rates for tobacco withdrawal that are often <15% (Glassman et al., 1993; 
Hall, Munoz, Reus, & Sees, 1993; Rohde et al., 2004; Ziedonis & George, 1997; Ziedonis et al., 
1994). Moreover, smoking tobacco is a significant predictor for a lifetime-suicidal tendency, 
even when monitoring possible confounders (Breslau et al., 2005; Oquendo et al., 2004; 
Bronisch et al., 2009; Miller et al., 2000; figure 4).  
 
 
Fig. 3. Smoking and suicide risk (Miller et al., 2000) 
The etiological causality of this coincidence between smoking tobacco and mental disorders is 
largely unresolved. Three competing theoretical models are being discussed: 1) According to 
the 'primary disorder model' smoking is a reaction to the mental disorder (Guidelines of the 
American Psychiatric Association, 1996; Kendler et al., 1993; Pomerleau et al., 1997). In the 
sense of the ‘self treatment hypothesis’, persons suffering from mental strain use nicotine for 
stress reduction (easing effect of nicotine) and for alleviating their subjective mental 
symptoms (effect of nicotine to soothe, enhance moods and improve the well-being of 
smokers) (Kendler et al., 1993; Hughes, 2004; Breslau, 2001). It is true that nicotine has 
specific anti-depressive effects (Tizabi et al., 1999; Balfour et al., 2000), since the serotonergic 
system is activated by nicotine similar to antidepressants (Vazquez-Palacios et al., 2005), and 
it is often used by psychiatric patients to specifically enhance their mood. According to this 
model, initial manifestation of the mental disorder would have to precede chronological 
tobacco smoking. 2) In contrast, the 'primary smoking model' states that smoking can 
contribute to the development of a mental disorder. According to that, exposition to nicotine 
is a risk factor making individuals vulnerable to mental disorders due to the chronic impact 
on diverse transmitter systems that are involved in the development of mental disorders. 
This hypothesis is supported by the observation that the initial manifestation of mental 
symptoms often follows a longer break of regular smoking. Furthermore, for example, 
prenatal exposition to smoking is associated with the later occurrence of ADHD and 
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depression in infancy and adolescence. 3) The 'bidirectional model' assumes a long lasting 
interaction effect between smoking and mental disorders. Therefore, smoking triggers the 
development of mental symptoms in genetically disposed persons first and is later used for 
easing symptoms. In this way, regular nicotine consumption contributes to the 
chronification of the disorders in the long term (Mueser et al., 1998). It could be possible that 
smokers with mental disorders shy away from smoke stop because nicotine withdrawal 
symptoms contribute to an exacerbation of psychiatric symptoms and an increase of the 
relapse risk (Glassman, 2001; Balfour et al., 2000). Finally, it has been proven that e.g. 
schizophrenic patients often use nicotine to specifically counter regulate the effect of 
neuroleptics (Barnes et al., 2006; Glassman, 1994; Haring, Barnas, Saria, Humpel, & 
Fleischhaker, 1989; Hughes, 1993). 4) Finally, the 'common-factor model' assumes a common 
etiology of nicotine dependence and other mental disorders (Breslau et al., 1998; Dierker, 
2002; Covey, 1998). Since nicotine dependence itself is a mental disorder with manifold 
commonalities in terms of neurobiological, cognitive personal or social risk factors and 
mechanisms with a) other substance disorders (e.g. dopaminergic system) and also b) with 
other mental disorders (e.g. serotonergic system in MD), a common genetic disposition for 
e.g. depressions and susceptibility for the effects of nicotine positive seems likely (Kendler et 
al., 1993; Breslau et al., 1998). 
2.3 Etiology: Neurobiological and psychological addiction mechanisms 
2.3.1 Vulnerability and risk factors 
Today, the average age of onset for smoking cigarettes ranges between eleven to thirteen 
years (Silagy et al., 1994; Nelson et al., 1998). The development of a tobacco addiction is 
dependent on a number of factors or causes. In addition to a genetic disposition (e.g. number 
of receptors, availability of specific enzymes, and function of transmitter systems), multiple 
acquired vulnerabilities and risk factors have been identified that comprise individual 
characteristics as well as specific environmental conditions (Brown et al., 1992; US 
Department of Health and Human Services, 1990). In the stage of initial or experimental use, 
despite of availability of tobacco products and advertising influences, social factors like  family 
models and the peer group that are decisive for the start of one’s smoking  (Silagy et al., 1994). 
There are significant differences in social classes with the highest smoking rates in the lower 
social class, in unemployed people and social groups with lower educational achievement. 
Furthermore, an existing psychiatric comorbidity and unfavourable influences of the family 
milieu (parental psychopathology) primarily count towards the individual risk factors for 
the development of a tobacco addiction (WHO, 2001). Moreover, tobacco addiction and 
health risks towards smoking-related disorders correlate with the early onset of smoking. The 
physical addiction phenomena seem to develop especially rapidly in children and 
adolescents. In the stage of regular and dependent use, smokers try to manage their psycho-
social stress or daily hassles by using nicotine (‘self treatment’). In the long term run, the most 
important condition to maintain dependency is negative reinforcement, because every 
cigarette acts more and more to reduce withdrawal symptoms in the first line. 
2.3.2 Neurobiological mechanisms 
Like all psychotropic substances, nicotine stimulates the mesolimbic dopamine system (‘desire 
and reward system’) whose neurones are located in the area tegmentalis ventralis and project 
to the nucleus accumbens as well as the corpus striatum, among others. In contrast to other 
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drugs, nicotine exposition initiates a particular long term potentiation of specific neurons in 
this area of the brain, which causes a persistent increase of the dopamine level even after 
short term nicotine exposition.  
In order to compensate for the artificial biochemical flooding and to maintain the normal 
functions, the brain reacts on two levels: 1) with a neuroanatomical change of the number 
and responsiveness of specific receptors (neuroplastic down or up regulation) and 2) with an 
inhibiting feedback on the level of transmitters, restricting the effect of nicotine by releasing 
counter-regulative molecules (Kunze et al., 1998). Both reactions lead to a weakening of the 
effect of nicotine. If the smoker subsequently tries to compensate the diminishing effect by 
means of more intensive smoking, the brain respectively produce more inhibiting molecules 
in that ever-increasing doses of nicotine are necessary to achieve ‘intoxication’ (tolerance). If 
the organism is then suddenly deprived of the substance (withdrawal), the balance of the 
system is forcefully disturbed. On the one hand, too few bodily-owned transmitters are 
available since the body has limited its own production and, on the other hand, a surplus of 
compensatorily released inhibitory molecules, which further inhibit the normal remaining 
functions of the transmitter balance, exist for a number of weeks. A strong state of deprivation 
results thereof and causes torturing mental and physical acute withdrawal conditions 
(withdrawal syndrome). The body is now not able to exist without tobacco any more and, 
therefore, an addiction has formed.  
2.3.3 Psychological and neuropsychological mechanisms 
Addicted ex-smokers are still at risk to relapse in face of any smoking-associated cues which 
trigger an irresistible desire (craving) for nicotine, even many years and decades after the 
withdrawal, probably for their whole lifetime. This long time active ‘addiction memory’ 
cannot be explained by mechanism of physical dependence, which normalise within a few 
weeks after quitting. In the first line, complex learned conditioning processes are responsible 
for the continuing sensitisation to nicotine and the ongoing high relapse rates. 
Simultaneously to dopamine release in the ‘desire and reward system’ nicotine stimulates 
specific areas in the brain which are involved in association learning processes. That is why 
smoking tobacco has a particularly strong link to situational (smoking break, coffee drinking, 
after work beer), behavioural (reaching for the box of cigarettes), sensory (smell, taste) or 
affective (mood) cues that are associated with smoking. Insofar, persistent addiction can be 
primarily traced back to respondent and operant conditioning. In the case of smoking positive 
reinforcement is generated by the fateful association between the inhalation (stimulus) and 
the subsequent state of well-being (response) that permanently becomes engraved in 
memory (’addiction memory’) within a short time. Despite the missing intensive intoxication, 
the high addiction potential of tobacco smoking results from the brain of a regular smoker 
being flooded with nicotine 200 to 400 times per day (per year: 73,000 to 146,000 times) — 
and the stimulus-response connection is thereby continuously enforced. 
The high risk of a relapse and the actual relapse process after a smoke stop can be explained by 
means of neuropsychological and cognitivepsychological models. However, one of the main -
questions, why the addiction behaviour and craving is not extinguished after a certain time 
was not resolved satisfactorily. The latest research in cognitive learning shows that the 
extinction of a respondent conditioning is, in a neurobiological sense, no unlearning in terms 
of a decoupling of synaptic links but a new learning and/or re-learning where new stimulus-
reaction-links are generated while the old ones are principally still available (Conklin & 
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Tiffany, 2002).  That is why old addiction conditionings can, if certain triggers emerge, be 
reactivated even after a long time (e.g. by reinstatement or spontaneous recovery). 
Furthermore, the hypersensitivity to the addiction cues (cue reactivity), which is profoundly 
resistant against extinction and overwriting, can be explained with neuroplastic changes in the 
dopamine system. In the case of chronic substance intake a neurobiological hyper reactivity 
to the drug and their trigger cues develops in the mesolimbic dopamine system (subcortical 
dysfunction) and, at the same time, the areas that are responsible for executive control (frontal 
cortical dysfunction) are weakened. Finally, the relapse can be described by the different 
levels of information processing of addiction-related cues on the one hand, and by the 
intentional control of action on the other (Tiffany und Conklin, 2000). The addicts’ reaction 
to drug-associated cues is an example of ‘automatic processing’, i.e. it is made unconsciously 
quick, linked to certain trigger situations, with a low use of cognitive capacity and can only 
be influenced to a small degree. In contrast, abstinence demands an intentional regulation of 
action with conscious information processing and executive control functions (‘controlled 
processing’), which is consciously, intention controlled and flexible, but relatively slow, 
cognitively demanding and limited by the processing capacity. In case of chronic substance 
abuse an increasing disequilibrium between the growing influence of automatic stimulus 
processing (‘implicit cognitions’), as well as a weakening of executive control and regulation 
of emotions that makes the person trying to quit increasingly vulnerable to addiction 
triggers and, finally, relapse. 
2.4 Treatment 
Almost all smokes are aware of the smoke-related health risks and a majority of them 
repeatedly tries to stop smoking. The willingness to quit depends on the individual stage of 
motivation. According to the widely known transtheoretical model (Prochaska & DiClimente, 
1993) smokers move through a discrete series of five motivational stages before they quit 
successfully: (i) precontemplation (no thoughts of quitting), (ii) contemplation (thinking about 
quitting), (iii) preparation (planning to quit in the next 30 days), (iv) action (quitting 
successfully for up to six months), and (v) maintenance (no smoking for more than six 
months). The transtheoretical theory has not been empirically supported, and some authors 
cast doubt its practical value (Etter & Sutton, 2002; Sutton, 2001).  
However, most smokers will succeed to quit at one point in their life: There are more ex-
smokers than current smokers to be found in the age cohort over 50 years old. However, 
tobacco withdrawal often requires a multitude of stop smoking trials to be successful when 
no professional help is sought. The success rate of unassisted smoke stop trials is at a mere 
3-6% during the 12-months period. However, less than 5 % of all smokers willing to stop 
make use of professional help, despite the availability of effective smoking cessation 
therapies (WHO, 2001; Nelson & Wittchen, 1998). 
Professional smoking cessation treatments include a wide range of interventions, from medical 
advice through to brief motivational interventions to complex withdrawal programs. In 
practice, less effective methods such as hypnosis and acupuncture are used alongside 
motivational interviewing, cognitive-behavioural therapy interventions (CBT) and 
medicinal approaches in withdrawal and substitution treatment. Professional smoking 
cessation treatment is first and foremost based on behavioural group interventions (cf. Box 
1) and approaches of motivational interviewing, and often offered in combination with 
medicinal support (e.g. nicotine substitutes).  
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1. Psychoeducation: education, information and attitude change
2. Analysis of problem and behaviour: Analysis and documentation of smoking 
behaviour and the maintaining cognitive and situational or social conditions 
3. Strengthening of motivation to change (motivational interview): Clear decision to quit 
smoking, determination of a deadline to stop smoking 
4. Systematic preparation for abstinence, execution of smoke stop and modification of 
behaviour: Control of conditioning stimuli, development and training of alternative 
behaviour, contract management, self-reward, teaching of strategies of self-control 
5. Activation of a supporting social network and teaching of health promotional 
behaviour 
6. Relapse prevention: Dealing with risk situations, strategies against relapse risks (role 
play exercises) 
Box 1. Components of complex behavioural therapy programmes for smoking cessation. 
Primary goal in smoking cessation treatment is total abstinence. Controlled tobacco use 
leading to harm reduction is only aimed for in exceptional cases (in cases of severe disease 
or pregnancy with simultaneous inability to remain abstinent; Stead & Lancaster, 2007; 
Lumley et al., 2009). The medicinal treatment in smoking cessation primarily aims to soothe 
the somatic withdrawal symptoms and associated craving. The pharmacological treatment 
options are based on three different modes of action:  
i. In nicotine replacement therapy a patient is given nicotine doses, which substitute the 
nicotine the patient does not take in anymore by smoking, by means of drugs 
containing nicotine (nicotine patch, gum, inhaler, lozenge, nasal spray, sublingual 
tablet). By means of retaining an equal level of nicotine withdrawal symptoms are 
soothed and the withdrawal is made easier by stepwise downdosing the 
pharmacological nicotine. 
ii. The nicotine-free drug bupropion (Zyban®), originally developed as anti-depressant, 
inhibits the synaptic absorption of catecholamines (adrenalin, dopamine) in the 
mesolimbic dopamine system, thereby compensating the dopamine lack caused by the 
nicotine withdrawal and, in this way, soothes the withdrawal symptoms without 
supplying nicotine. Due to serious contra-indications, side-effects and pharmaceutical 
risks, bupropion may only be applied under medical supervision.  
iii. The partial agonist varenicline (Chantix®) binds to specific nicotine receptors of the 
subtype that is responsible for one of the addictive effects of the nicotine. The active 
agent stimulates the receptors and thereby eases withdrawal symptoms. At the same 
time, it inhibits the effect of externally supplied nicotine by blocking the receptors. Also 
due to the serious side-effects and risks (nausea, headache, insomnia, abnormal dreams, 
suicidal ideation and occasional suicidal behavior, erratic behavior and drowsiness) 
there are similarly strict regulations for varenicline in terms of prescription and medical 
supervision. 
Multi-modal smoking cessation programmes can be divided into three stages: (i) reinforcement 
of the abstinence motivation and the patient’s commitment to quit smoking, (ii) preparation 
and realisation of smoke stop, (iii) maintenance of abstinence and using new coping 
strategies to avoid a return to use. 
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i. Regular smokers generally are ambivalent towards quitting. Although almost every 
smoker is aware of the health risks and further disadvantages of smoking, most of 
them dread the burdens associated with smoke stop (fear of withdrawal symptoms 
and loss of positive reinforcement) and continually postpone their withdrawal, often 
for years. This is why it is necessary to make an explicit decision pro tobacco 
withdrawal at the beginning of the withdrawal stage (in case of smokers willing to 
stop) and/or to motivate in favor of a smoke stop (in case of smokers not yet willing 
to stop). For this purpose, motivational interviewing is a suitable approach (Miller & 
Rollnick, 2002 by which the motivation to quit smoking and the confidence to change 
can be analysed and systematically strengthened during the preparation stage. In 
smoking cessation practice, behavioural-therapeutic techniques (smoking diaries, 
behavioural analysis, CO-measurement, reinforcement plans, pros-cons lists, target 
hierarchies, aim in life analysis, short and long term benefits, strengthening of self-
efficacy) as well as cognitive techniques (disputation of irrational ideas, worst case 
scenarios, development of rational alternatives) are applied for the preparation of the 
smoke stop. The explicit commitment of the smoker to his/her desire to quit smoking 
(importance) and his belief to being able to reach this goal (realisability) proves to be 
decisive in this stage. 
ii. During the quitting stage the smoker is systematically prepared for the smoke stop and 
the time of abstinence. For this purpose, it is important, not only to create adequate 
commitment but also to enhance the optimism about one's ability to change and to 
strengthen self efficacy. Using the ‘cold turkey method’, a certain quit day is 
determined. In the sense of a stimulus control, all triggers (smoke utensils such as 
ashtray, cigarette boxes, lighter etc.) are removed from the immediate surrounding 
and/or typical smoke situations (e.g. local pub) are temporarily avoided for the time of 
the smoke stop preparation stage. The smoke stop can be supported by means of 
aversion therapy (excessive inhaling, retain smoke in lung, smelling of containers with 
cigarette butts and cold ash) or counter conditioning (presentation of unpleasant stimuli 
such as deterring photos of smoke-related diseases contingent to smoking). 
iii. The treatment stage most important to keep long term abstinence is the maintenance 
and relapse prevention. The ex-smoker is supported in his/her self control management 
(response control) and self instruction in order for him/her to master craving and 
withdrawal symptoms and to successfully cope with high risky situation (refusal 
training). At the same time, positive alternatives to smoking (relaxation exercise, 
physical exercise, easy breathing, water drinking, pleasant activities and attentional 
distraction) are proposed and trained. Positive stimuli (e.g. appraisal, material 
rewards, amount of money saved, improvement of lung function, duration of 
abstinence) or contracting (written commitment, rewards vs punishment) are used to 
support abstinence and social resources are mobilised (workshop assistants, 
supporters). During abstinence a cognitive reframing shall be triggered in which the 
smokefree life comes to be seen as less unpleasant condition of withdrawal and loss 
but increasingly as an awarding situation in which a positive physical well-being and 
independence dominates. Finally, an individual emergency plan is drafted and 
structured relapse prevention management is trained (what to do when having a 
relapse). 
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2.5 Empirical evidence 
Up to date, a large amount of professional and more or less evidence-based smoking cessation 
treatments have been developed, that range from minimal interventions (physician’s advice 
to quit smoking) and medicinal withdrawal treatment (nicotine replacement therapy, 
psychotropic drugs such as bupropion or varenicline) to telephone counselling (‘quit-line’) 
and online quitting programmes as well as to multi-modal smoking cessation in behavioural 
group therapy described above. The efficacy of professional smoking cessation treatments is 
well determined. An impressive number of RCTs as well as several meta-analyses and 
Systematic Cochrane Reviews clearly proved the high efficacy of several cessation treatments 
towards the primary outcome of long-term abstinence.  
In particular, group behaviour therapy programmes for smoking cessation yielded high effect 
sizes in many randomised controlled trials (RCT) and were found to be superior to self help, 
and other less intensive interventions (Stead & Lancaster, 2005). However, there is not enough 
evidence to evaluate whether groups are more effective, or cost-effective, than intensive 
individual counselling and only limited evidence that the addition of group therapy to other 
forms of treatment, such as advice from a health professional or nicotine replacement, 
produced extra benefit (Stead & Lancaster, 2005, p 2). Individual behavioural counselling 
interventions for smoking cessation have been well-proven, too (Lancaster & Stead, 2005). 
Individual counselling was more effective than control, but a greater effect of intensive 
counselling compared to brief counseling could not be found. Aversion therapy, which pairs the 
pleasurable stimulus of smoking a cigarette with some unpleasant stimulus in order to 
extinguish the urge to smoke, has been evaluated in a smaller number of RCT’s that provide 
insufficient evidence to determine the efficacy of rapid smoking (Hajek & Stead, 2001).  
Pharmaceutical treatment in smoking cessation is high efficient as well. All of the commercially 
available forms of nicotine replacement therapy (gum, transdermal patch, nasal spray, inhaler 
and sublingual tablets/lozenges) can help people who make a quit attempt to increase their 
chances of successfully stopping smoking by 50-70%, regardless of setting Stead et al., 2008). 
The empirical evidence show that the antidepressants bupropion and nortriptyline are equally 
effective and of similar efficacy to nicotine replacement therapy, but there is insufficient 
evidence that adding bupropion to nicotine replacement therapy provides an additional long-
term benefit (Hughes et al., 2007, p 2). Also varenicline at standard dose increases the chances of 
successful long-term smoking cessation between two- and threefold compared with 
pharmacologically unassisted quit attempts (Cahill et al., 2011, p 2).  
The trials to internet-based interventions for smoking cessation did not show consistent effects, 
but for some interventions there is evidence that online counselling can assist smoking 
cessation, especially if the information is appropriately tailored to the users and frequent 
automated contacts with the users are ensured (Civljak, Sheikh, Stead & Car, 2010, p 2). 
Similarly, proactive telephone counselling for smoking cessation can efficiently help smokers in 
quitting, but a minimum of three or more calls are required to increase the chances of quitting 
compared to a minimal intervention (providing standard self-help materials, brief advice), or 
compared to pharmacotherapy alone (Stead et al., 2006). Motivational interviewing for smoking 
cessation yielded a modest but significant increase in quitting compared to brief advice or 
usual care and was more effective, when delivered by primary care physicians and by 
counselors and when conducted in longer and multiple sessions (Lai et al., 2010). 
In contrast, there is no consistent, bias-free evidence that acupuncture, acupressure, laser 
therapy or electrostimulation or exercise interventions for smoking cessation are effective for 
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smoking cessation (White et al., 2011; Ussher et al., 2008). Also, the empirical evidence for 
hypnotherapy fails to show a greater effect on six-month quit rates than other interventions or 
no treatment (Barnes et al., 2010). Standard self-help materials may increase quit rates 
compared to no intervention, but the effect is likely to be small, and no additional benefit 
has been found alongside other interventions such as advice from a healthcare professional, 
or nicotine replacement therapy (Lancaster & Stead, 2005, p 2). Materials that are tailored for 
individual smokers are more effective than untailored materials, although the absolute size 
of effect is still small. 
Smoking reduction versus abrupt cessation in smokers who want to quit makes no difference 
with regard to long-term abstinence (Lindson et al., 2010). According to the transtheoretical 
model stage-based self-help interventions (expert systems and/or tailored materials) and 
individual counselling were neither more nor less effective than their non-stage-based 
equivalents (Cahill et al., 2010, p 2). 
 
 
Fig. 4. Success rates (12-months abstinence) of measurements for tobacco withdrawal in 
clinical studies (efficacy) according to a meta-analysis of the US Department of Health and 
Human Services (Fiore et al., 2008) 
In context of the US Clinical Practice Guidelines, sponsored by the U.S. Public Health Service, 
Guideline Panel conducted 2000 a large mega-metanalysis ‘Treating Tobacco Use and 
Dependence’ which has been updated in 2008 (Fiore et al., 2008). The main results are shown 
in figure 7. In Detail, the effectiveness and abstinence rates of various interventions and 
medications in smoking cessation treatment are presented in table 6 and 7. In summary, the 
most effective smoking cessation treatment is a combination of group behavior therapy or 
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individual counseling with pharmaceutical treatment, whereas a combination of more than 
one pharmaceutics has an extra benefit (e.g., NRT patch + NRT gum or NRT patch + oral 
medication). 
Based on the empirical evidence of international trials in the field of smoking, tobacco 
dependence and smoking cessation in numerous countries specific clinical guidelines for 
treating tobacco addiction have been developed during the last decade, e.g. : 
 The well-known US ‘Clinical Practice Guideline for Treating Tobacco Use and Dependence’ 
(Fiore et al., 2000, 2008) occurred as a result of an extraordinary partnership among 
Federal Government and nonprofit organizations; 
 in UK the National Institute for Health and Clinical Excellence – NICE created a 
number of clinical guidelines: 
 Smoking cessation services in primary care, pharmacies, local authorities and 
workplaces, particularly for manual working groups, pregnant women and hard to 
reach communities (2008) 
 The Impact of Quitlines on Smoking Cessation (2007) 
 Economic Analysis of Interventions for Smoking Cessation Aimed at Pregnant 
Women (2007) 
 School-based interventions to prevent the uptake of smoking among children and 
young people: cost-effectiveness model (2010) 
 The effectiveness of smoking cessation interventions to reduce the rates of 
premature death in disadvantaged areas through proactive case finding, retention 
and access to services 
 Mass-media and point-of-sales measures to prevent the uptake of smoking by 
children and young people (2008) 
 Workplace health promotion: how to help employees to stop smoking (2007) 
 Association of the Scientific Medical Societies in Germany co-ordinates the national 
programme of medical guidelines of its member organizations. In cooperation with 
numerous institutions and non-profit organizations (e.g. German Society of Addiction 
Research; German Association for Psychiatry and Psychotherapy) two smoking 
cessation guidelines have been developed: 
 Guidelines for Treating Substance Use Disorders (2004) 
 Smoking Cessation in COPD patients (2008) 
These various national guidelines do explicitly consider the different conditions of the 
social, cultural or health care systems in each country and should be received by the health 
care professionals in the specific region they are developed for.  
 
Various intensity levels of session length (n = 43 studies)a 
Level of contact 
Number of 
arms 
Estimated odds ratio 
(95% C.I.) 
Estimated abstinence 
rate 
(95% C.I.) 
No contact 30 1.0 10.9 
Minimal counseling  
(< 3 minutes) 
19 1.3 (1.01–1.6) 13.4 (10.9–16.1) 
Low-intensity 
counseling 
 (3–10 minutes) 
16 1.6 (1.2–2.0) 16.0 (12.8–19.2) 
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Higher intensity 
counseling 
 (> 10 minutes) 
55 2.3 (2.0–2.7) 22.1 (19.4–24.7) 
Total amount of contact time (n = 35 studies) a 
Total amount of 
contact time 
Number of 
arms 
Estimated odds ratio 
(95% C.I.) 
Estimated abstinence 
rate 
(95% C.I.) 
No minutes 16 1.0 11.0 
1–3 minutes 12 1.4 (1.1–1.8) 14.4 (10.3–17.5) 
4–30 minutes 20 1.9 (1.5–2.3) 18.8 (15.6–22.0) 
31–90 minutes 16 3.0 (2.3–3.8) 26.5 (21.5–31.4) 
91–300 minutes 16 3.2 (2.3–4.6) 28.4 (21.3–35.5) 
> 300 minutes 15 2.8 (2.0–3.9) 25.5 (19.2–31.7) 
Various types of formats (n = 58 studies) a 
Format Number 
Number of 
arms 
Estimated odds ratio 
(95% C.I.) 
Estimated abstinence 
rate 
(95% C.I.) 
No format 20 1.0 10.8 
Self-help 93 1.2 (1.02–1.3) 12.3 (10.9–13.6) 
Proactive tel. counseling 26 1.2 (1.1–1.4) 13.1 (11.4–14.8) 
Group counseling 52 1.3 (1.1–1.6) 13.9 (11.6–16.1) 
Individual counseling 67 1.7 (1.4–2.0) 16.8 (14.7–19.1) 
Various types of counseling and behavioral therapies (n = 64 studies) a 
Type of counseling and 
behavioral therapy 
Number of 
arms 
Estimated odds ratio 
(95% C.I.) 
Estimated abstinence 
rate 
(95% C.I.) 
No counseling/ 
behavioral therapy 
35 1.0 11.2 
Relaxation/breathing 31 1.0 (0.7–1.3) 10.8 (7.9–13.8) 
Contingency contracting 22 1.0 (0.7–1.4) 11.2 (7.8–14.6) 
Weight/diet 19 1.0 (0.8–1.3) 11.2 (8.5–14.0) 
Cigarette fading 25 1.1 (0.8–1.5) 11.8 (8.4–15.3) 
Negative affect 8 1.2 (0.8–1.9) 13.6 (8.7–18.5) 
social support 50 1.3 (1.1–1.6) 14.4 (12.3–16.5) 
Extratreatment  
social support 
19 1.5 (1.1–2.1) 16.2 (11.8–20.6) 
Practical counseling 
(problem solving/skills)
104 1.5 (1.3–1.8) 16.2 (14.0–18.5) 
Other aversive smoking 19 1.7 (1.04–2.8) 17.7 (11.2–24.9) 
Rapid smoking 19 2.0 (1.1–3.5) 19.9 (11.2–29.0) 
a Go to www.surgeongeneral.gov/tobacco/gdinrefs.htm for the articles used in this meta-analysis.  
Table 6. Meta-analysis (2000): Effectiveness and abstinence rates of various interventions in 
smoking cessation treatment 
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Various medications and medication compared to placebo at 6-months post quit (n = 83 
studies) a 
Medication 
Number of 
arms 
Estimated odds ratio 
(95% C.I.) 
Estimated abstinence 
rate 
(95% C.I.) 
Placebo 80 1.0 13.8 
Monotherapies 
Varenicline (2mg/day) 5 3.1 (2.5–3.8) 33.2 (28.9–37.8) 
Nicotine Nasal Spray 4 2.3 (1.7–3.0) 26.7 (21.5–32.7) 
Hig-Dose Nicotine Patch  
(> 25mg) (These include 
both standard or ling-
term-duration) 
4 2.3 (1.7–3.0) 26.5 (21.3–32.5) 
Long-Term Nicotine 
Gum (>14 weeks) 
6 2.2 (1.5–3.2) 26.1 (19.7–33.6) 
Varenicline (1mg/day) 3 2.1 (1.5–3.0) 25.4 (19.6–32.2) 
Nicotine Inhaler 6 2.1 (1.5–2.9) 24.8 (19.1–31.6) 
Clonidine 3 2.1 (1.2–3.7) 25.0 (15.7–37.3) 
Bupropion SR 226 2.0 (1.8–2.2) 24.2 (22.2–26.4) 
Nicotine Patch (6–14 
weeks) 
632 1.9 (1.7–2.2) 23.4 (21.3–25.8) 
Long-Term Nicotine 
Patch (> 14 weeks) 
3102 1.9 (1.7–2.3) 23.7 (21.0–26.6) 
Nortriptyline 5 1.8 (1.3–2.6) 22.5 (16.8–29.4) 
Nicotine Gum (6–14 
weeks) 
15 1.5 (1.2–1.7) 19.0 (16.5–21.9) 
Combination therapies 
Patch (long-term; > 14 
weeks) + ad llb NRT 
(gum or spray) 
3 3.6 (2.5–5.2) 36.5 (28.6–45.3) 
Patch + Bupropion SR 3 2.5 (1.9–3.4) 28.9 (23.5–35.1) 
Patch + Nortriptyline 2 2.3 (1.3–4.2) 27.3 (17.2–40.4) 
Patch + Inhaler 2 2.2 (1.3–3.6) 25.8 (17.4–36.5) 
Patch + Second 
generation 
antidepressants 
(paroxetine, venlafaxine)
3 2.0 (1.2–3.4) 24.3 (16.1–35.0) 
Medications not shown 
to be effective 
   
Selective Serotonin Re-
uptake Inhibitors (SSRIs)
3 1.0 (0.7–1.4) 13.7 (10.2–18.0) 
Naltrexone 2 0.5 (0.2–1.2) 7.3 (3.1–16.2) 
a Go to www.surgeongeneral.gov/tobacco/gdinrefs.htm for the articles used in this meta-analysis.  
Table 7. Meta-analysis (2000): Effectiveness and abstinence rates of various medications in 
smoking cessation treatment 
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3. Conclusion  
The smoking rates in the population vary from country to country with a range between 
approximately 25-60% of adult population. Although only every third smoker meets the 
diagnostic criteria for nicotine dependence, tobacco addiction is the most prevalent mental 
disorder worldwide. Besides the well-known impact of tobacco smoking on physical health, 
there is a growing body of evidence that smoking increases the vulnerability for mental 
disorders, too. Point prevalence of tobacco smoking amongst persons with mental disorders 
(MD) is 40-50% and thus, on average, twice as high as amongst the general population. 
Smokers with psychiatric comorbidity do not only show increased somatic morbidity and 
mortality rates, but also a significantly worse prognosis in relation to their MD, up to a 
significant increase of lifetime suicide risks.  
The addiction potential of tobacco smoking as well as the difficulty to quit and to permanently 
remain abstinent is often highly underestimated by smokers themselves, but by many health 
care professionals as well. The high failure and relapse rates in smoking cessation, even in 
patients with life threatening smoking-associated disorders (e.g. myocardial infarction, 
pulmonary emphysema or lung transplantation) demonstrates that nicotine dependence is a 
serious mental disorder and an addiction comparable harmful like in case of illicit drugs. 
Overcoming smoking as a serious ’substance use disorder’ in many cases calls for 
professional cessation treatment. Although every second smoker succeeds to quit at some point 
in his/her life without professional help, however, this is only achieved after many years 
and after a number of failed trials. During this long lasting period since smokers are 
successful in quitting, in many cases serious harm to their physical or mental health has 
already been caused. Therefore, in routine care, smokers should be encouraged to quit smoking 
at an early stage and they should be tested on a routine basis for a tobacco addiction and, if 
necessary, be referred to a smoking cessation specialist or an outpatient cessation clinic. 
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